Abrysvo Generic Name & Formulations
Kits—1, 5, 10 (w. supplies)
Mechanism of Action
Abrysvo induces an immune response against RSV pre F that protects against lower respiratory tract disease caused by RSV.
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. Active immunization for the prevention of LRTD caused by RSV in adults aged ≥60yrs.
Abrysvo Dosage and Administration
Pregnant individuals (32–36 weeks gestational age) or Adults (≥60yrs): one single dose (0.5mL) by IM inj.
<18yrs: not established.
Abrysvo Boxed Warnings
Potential risk for preterm birth; use only as indicated. Have appropriate medical treatment available. Syncope. Immunocompromised. Vaccination may not protect all recipients. Pregnancy. Nursing mothers.
Concomitant immunosuppressants: may get suboptimal response.
Abrysvo Adverse Reactions
Fatigue, headache, inj site pain, muscle pain; anaphylaxis.
Abrysvo Clinical Trials
Abrysvo Patient Counseling